Marshall Wace LLP Raises Stock Position in Chimerix, Inc. (NASDAQ:CMRX)

Marshall Wace LLP raised its position in shares of Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 1,318.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,213,940 shares of the biopharmaceutical company's stock after purchasing an additional 2,057,864 shares during the quarter. Marshall Wace LLP owned about 2.46% of Chimerix worth $7,705,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Bender Robert & Associates acquired a new position in Chimerix during the fourth quarter worth about $37,000. Stoneridge Investment Partners LLC grew its holdings in Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock worth $154,000 after acquiring an additional 8,134 shares during the period. Charles Schwab Investment Management Inc. acquired a new position in Chimerix during the fourth quarter worth about $183,000. Palumbo Wealth Management LLC acquired a new position in Chimerix during the fourth quarter worth about $221,000. Finally, Valeo Financial Advisors LLC grew its holdings in Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock worth $509,000 after acquiring an additional 64,420 shares during the period. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Stock Performance

NASDAQ CMRX remained flat at $8.54 during trading on Monday. The stock has a fifty day moving average of $7.86 and a two-hundred day moving average of $4.34. The company has a market capitalization of $801.09 million, a P/E ratio of -9.09 and a beta of -0.17. Chimerix, Inc. has a one year low of $0.75 and a one year high of $8.55.

Chimerix (NASDAQ:CMRX - Get Free Report) last issued its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.31 million. On average, equities analysts expect that Chimerix, Inc. will post -0.99 EPS for the current year.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders sold 20,760 shares of company stock valued at $91,175. Company insiders own 13.10% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on CMRX. Jefferies Financial Group reissued a "hold" rating and issued a $8.50 price target (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush reissued a "neutral" rating and issued a $8.55 price target (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com assumed coverage on Chimerix in a research note on Thursday. They issued a "sell" rating on the stock. Finally, HC Wainwright restated a "neutral" rating and set a $8.55 price objective (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.